热门资讯> 正文
比较锐佳制药（纳斯达克股票代码：RIGL）和 Purple Biotech（纳斯达克股票代码：PPBT）
2023-03-31 13:32
Rigel Pharmaceuticals (NASDAQ:RIGL – Get Rating) and Purple Biotech (NASDAQ:PPBT – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.
Institutional and Insider Ownership
73.9% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.6% of Purple Biotech shares are owned by institutional investors. 6.4% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Get Rigel Pharmaceuticals alerts:Earnings and Valuation
This table compares Rigel Pharmaceuticals and Purple Biotech's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rigel Pharmaceuticals | $120.24 million | 1.94 | -$58.57 million | ($0.34) | -3.94 |
| Purple Biotech | $1.00 million | 31.97 | -$21.67 million | ($1.21) | -1.43 |
Purple Biotech has lower revenue, but higher earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Rigel Pharmaceuticals and Purple Biotech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rigel Pharmaceuticals | 0 | 4 | 3 | 0 | 2.43 |
| Purple Biotech | 0 | 0 | 2 | 0 | 3.00 |
Rigel Pharmaceuticals presently has a consensus price target of $4.21, indicating a potential upside of 214.05%. Purple Biotech has a consensus price target of $9.00, indicating a potential upside of 420.23%. Given Purple Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Purple Biotech is more favorable than Rigel Pharmaceuticals.
Risk & Volatility
Rigel Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500.
Profitability
This table compares Rigel Pharmaceuticals and Purple Biotech's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rigel Pharmaceuticals | -48.71% | -2,419.00% | -44.46% |
| Purple Biotech | N/A | -39.60% | -35.00% |
Summary
Purple Biotech beats Rigel Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Rigel Pharmaceuticals
(Get Rating)
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
About Purple Biotech
(Get Rating)
Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
